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Background: The ever-increasing expanse of online bioinformatics data is enabling new ways to, not only explore
the visualization of these data, but also to apply novel mathematical methods to extract meaningful information for
clinically relevant analysis of pathways and treatment decisions. One of the methods used for computing topological
characteristics of a space at different spatial resolutions is persistent homology. This concept can also be applied to
network theory, and more specifically to protein-protein interaction networks, where the number of rings in an
individual cancer network represents a measure of complexity.
Results: We observed a linear correlation of R = −0.55 between persistent homology and 5-year survival of patients
with a variety of cancers. This relationship was used to predict the proteins within a protein-protein interaction network
with the most impact on cancer progression. By re-computing the persistent homology after computationally
removing an individual node (protein) from the protein-protein interaction network, we were able to evaluate
whether such an inhibition would lead to improvement in patient survival. The power of this approach lied in its
ability to identify the effects of inhibition of multiple proteins and in the ability to expose whether the effect of a
single inhibition may be amplified by inhibition of other proteins. More importantly, we illustrate specific examples
of persistent homology calculations, which correctly predict the survival benefit observed effects in clinical trials
using inhibitors of the identified molecular target.
Conclusions: We propose that computational approaches such as persistent homology may be used in the future
for selection of molecular therapies in clinic. The technique uses a mathematical algorithm to evaluate the node
(protein) whose inhibition has the highest potential to reduce network complexity. The greater the drop in
persistent homology, the greater reduction in network complexity, and thus a larger potential for survival benefit.
We hope that the use of advanced mathematics in medicine will provide timely information about the best drug
combination for patients, and avoid the expense associated with an unsuccessful clinical trial, where drug(s) did
not show a survival benefit.
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Over the past 50 years a large amount of genomic, prote-
omic and pathway information has become available.
While the information is detailed, it is very fragmented
and correlations with available epidemiological data are
slow to emerge. We have shown previously that the
complexity of cancer protein-protein interaction (PPI)
networks can be quantified by degree-entropy, a statis-
tical metric, strongly correlated with cancer patient sur-
vival [1]. The concept was validated by similar findings
by Takemoto, who has shown that modularity correlates
with survival [2]. We now explore the use of new topo-
logical measures known as persistent homology [3] and
cycle-basis [4] on protein-protein interaction (PPI) net-
works and their interpolation on survival.
The manuscript provides evidence that network com-
plexity, as represented by persistent homology and
cycle-basis, is not only correlated with survival rates of
cancer patients (i.e. the more complex the network the
worse the survival), but also that the removal of specific
proteins from the network (i.e. surrogate of protein in-
hibition in clinic) can lead to a decrease in network
complexity. Because complexity correlates with survival,
changes in network complexity caused by removal of
specific proteins from the protein-protein interaction
networks can be used to calculate gains or losses in sur-
vival. We propose to use these mathematical predictions
of improvements in survival for selections of protein
stimulators/inhibitors to use with therapeutic intent. For
example, we have found that while the elimination of a
node from the PPI network lowered the degree-entropy
[1], the change was too small to translate to an improve-
ment in survival rate. However, the elimination of indi-
vidual proteins from the PPI network and re-computing
the persistent homology, as opposed to degree-entropy,
enhanced the ability to predict the importance of spe-
cific proteins in the network and its potential effect on
survival.
The manuscript explores the possibility that the evalu-
ation of network topology using a persistent homology
approach may lead to development of a predictive math-
ematical model for the optimization of treatment re-
sponse to targeted therapy. Even more importantly,
because more than one protein can be targeted at the
same time, the approach can be used for development of
combination therapies in cases where more than one
oncogenic mutation is present in a single tumor.
At present, several approaches to analyzing networks
are being explored. The use of conventional statistical
mechanics measures of complex networks [5] is well
established, and will not be reviewed here. We will,
however, briefly review two statistical metrics: degree-
entropy and betweenness-centrality. Degree-entropy has
been described previously [1] and is computed from theentropy of the degree for each node. Specifically the




p kð Þ1n p kð Þ½ 
where p(k) represents a probability distribution on the
nodes of the network, p(k) =Nk/N with Nk the number
of nodes with degree k and N is the total number of
nodes. Betweenness-centrality is a measure of the cen-
trality of a node. Given a network graph G(E,V) consist-
ing of nodes V and edges E, the betweenness-centrality
cB is a measure of the centrality of a node, v. Typically it
is the sum of the fractions of shortest paths that pass
through v and is given by:
cB ¼
X
s; t ∈ V
σ s; tjvð Þ
σ s; tð Þ
where σ(s, t) is the number of shortest paths between
two nodes (s,t) and σ(s, t|v) is the number of those paths
passing through nodes other than v.
In addition to the above-discussed statistical measures,
a well-known description of networks can be based on
graph spectra [5–8]. Typically, one computes the eigen-
values of the adjacency matrix (or the Laplacian matrix)
of the network graph. The spectral study is almost al-
ways associated with dynamical systems for investigating
the stability of the network. One well-known result is
that the multiplicity of zero eigenvalues of the graph
Laplacian is equal to the number of components in the
graph [9], and the number of components within the graph
is equal to a topological measure known as Betti [10].
Before discussing our topological approaches we briefly
mention an approach based on symmetry groups, because
it may be considered analogous to our approach, espe-
cially the automorphism group [9]. A set of automor-
phisms of a network graph Aut(G) forms a group, and the
cardinality (the number of elements) of the group
|Aut(G)| is a measure of the complexity of the network
graph. Typically, the automorphism group is decomposed,
or factored, into a minimum set of symmetry groups.
Given a graph G(V,E), an automorphism is a permutation
acting on the vertices. Those permutations that can pre-
serve the adjacency of vertices are called automorphisms.
Formally, an automorphism g of a graph G, has the prop-
erty that for two vertices u, and v, ug is adjacent to vg if
and only if, v is adjacent to u (i.e. an edge exists between
vertices u and v). These symmetry groups are sometimes
called motifs and are genuine symmetry groups, unlike
the motifs of Milo et al. [11]. The size of the automor-
phism group (the cardinality) correlates with cancer pa-
tient survival, but these symmetry groups are distinct
from the topological measure we now discuss.
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sistent homology.
1. Cycle-basis is the simplest topological measure of a
network. Paths in networks are sequences of vertices
that are connected by edges [5, 12], and may or may
not be self-intersecting. Paths that do not
self-intersect, self-avoiding walks, are called
geodesics and Hamiltonian paths. These self-avoiding
paths are of interest as they represent the cycle-basis
of a network. Each simple cycle C in a graph G has
associated with it a vector indexed on the edge set,
E(C). Each cycle forms an incident vector
bi Cð Þ ¼ 0; if ei ∉ E Cð Þ1; if ei ∈ E Cð Þ :
These incident vectors form a set spanning a binary
space CGF(2)(G) known as the cycle space of the
graph. As long as the vectors are linearly
independent, their incidence vectors are also linearly
independent over the binary space, GF(2), and the
independent set is called the cycle-basis [4, 13]. Two
independent manuscripts by Berger and by Kavitha
discuss an algorithm (implemented by Python-
NetworkX) the theoretical basis of which was first
described by Paton in 1969 [14].
2. Persistent homology is a more involved topological
measure of networks [3, 10, 15] an abstract
n-simplex {v0,⋯, vn} of a set of n + 1 called vertices.
Persistent homology can be geometrically
represented as the convex hull of these n + 1 vertices
in an n-dimensional Euclidian space. Simplices are
generalizations in any dimension of convex
polytopes such as points (0-simplices), segments
(1-simplices), triangles (2-simplices) and tetrahedra
(3-simplices). The faces of an n-simplex σ are all the
(n-1)-simplices, which are subsets of σ. For example,
a 3-simplex (tetrahedron) contains four 2-faces. A
simplicial complex K. is a collection of simplices such
that all the faces of each simplex are also in K. Given a
simplicial complex K and a field (in our case ℤ2ℤ), the
space of k-chains Ck is defined as the abstract vector
space generated by the k-simplices (that is, the vector
space of all formal sums λ1σ1 +… + λrσr with the λi∈ ℤ2ℤ
and the σi’s being k-simplices of K). On these vector
spaces the boundary operators ∂k :Ck→Ck − 1 are the
sum of the faces (with the convention that points have
empty faces). Notice that in our case, since the field is
ℤ
2ℤ, we don’t need to define an orientation on simplices.
Chains of dimension k that have null boundary
(i.e. chain in Zk := {c∈Ck; ∂k(c) = 0}) are called cycles
(Z for Zykel, cycle in German) and k -chains thatare the boundary of a k + 1 -chain (i.e. chains in
Bk := {b∈Ck; ∃ c∈Ck + 1, b = ∂k + 1(c)}) are called
boundaries. Notice that for any k ≥ 1 we have
∂k ∘ ∂k + 1 = 0 (i.e. Bk⊂Zk) since any boundary is a
cycle. The k -th homology group Hk is defined by
Hk ¼ Zk=Bk meaning that, starting from all the cycles,
the ones that are boundaries are killed when taking the
quotient. The dimension of the k-th homology group
is called the k-th Betti number and is denoted βk, and
the k-th Betti number records the number of
k-dimensional holes. The 0-th Betti number is the
number of connected components of the simplicial
complex. Given a filtration K1⊂⋯⊂Kn of embedded
simplicial complexes (an ordering), persistent
homology records homology classes persisting
between two indices i and j, i.e. cycles that remain
non-boundaries from i until at least j (these could
be killed by a boundary appearing later on). The
homology group of dimension k persisting from
i to j is defined by Hi;jk ¼ Zik= Zik ∩ Bjk
 
.
Its dimension is called the k -th Betti number persist-
ing from i to j and is denoted βk
i,j. In our analysis, only
dimension 0 and 1 Betti numbers were found of interest
and we will not consider here cases with k > 1.
Up to now, we have defined persistent homology for a
simplicial complex filtration; however, protein-protein
interaction networks do not appear as simplicial com-
plexes but rather as graphs (a set of vertices and a set of
edges). A simplicial complex can be built from a graph
in the following way. Associated with a graph is a dis-
tance d defined by the length of the shortest path between
two nodes (for our purpose, every edge is assumed to
have length 1), and this endows the graph with a metric
structure. The actual measure of persistent homology is
computed as a Rips complex - Kt associated with this
metric space, where parameter t is then defined by:
 Vertices are the points of the space (the nodes of
the network)
 An edge {v,w} belongs to Kt if and only if d(v,w) ≤
t, t ≥ 0
 A higher dimensional simplex is in Kt if all its faces
already belong to Kt
For our purpose, we will limit ourselves to parameters
t = (0,1,2,3), leading to Betti numbers β1
i,j, 0 ≤ i ≤ j ≤ 3.
To better understand what is encoded in the Betti
numbers let us look first at a simple illustrative network
presented in Fig. 1a. The red nodes and blue edges form
the network, and the yellow edges are added as the fil-
tration index increases. This simple network consists of
two cycles of length 4 connected by a triangle (a cycle of
length 3). The persistent homology (Betti numbers) of
Fig. 1 Example of Betti number calculation for a simple network. A simple network with red nodes and blue edges consists of two four-node
cycles connected via a three-node cycle (Panel a). The Betti number algorithm adds the yellow edges in calculation of filtration index effectively
“killing” the four-node cycles by eliminating the cycles. The numerical value for the Betti number is the number of bars lasting from index i to
index j in a Betti barcode. Each bar starts when a homology class is born and ends when this class is killed due to appearance in the filtration of
a higher dimensional chain whose boundary is the underlying cycle. Thus, Betti0 is equal to 9 and represents the number of nodes (Panel b), and
Betti1, is equal to 2, and represents the number of rings of four nodes (Panel c)
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so-called barcodes plotted against the filtration index (x-
axis). A bar starts when a homology class is born and
ends when this class is killed due to appearance in the
filtration of a higher dimensional chain whose boundary
is the underlying cycle. The measure for filtration index
zero, Rips complex K0, the graph contains as one dimen-
sional simplices the edges {n,m} such that d(n,m) ≤ 0
hence no edge at all and only the graph vertices (zero-
dimensional simplices) are included. These nine vertices
each account for one dimension in Z0
0 and B0
0 is empty.
Thus, there is one homology class per vertex, explaining
the nine bars lasting from 0 to 1 in Fig. 1b. These classes
persist until index one, at which they get all killed but
one. Indeed, K1 contains as one-dimensional simplices
the edges {n,m} such that d(n,m) ≤ 1, that is all the
edges of the graph (blue edges in Fig. 1a). Since the
graph has only one connected component, every pair of
two vertices is the boundary of a 1-chain and only one
homology class remains in H0
0,j for all j ≥ 1. This shows
that β0
0,j = 1 for j ≥ 1 and explains the only bar remaining
after index 1 in Fig. 1b. These considerations also dem-
onstrate that, for a general network, β0
0,j is the number
of connected components of the network, for any j ≥ 1.
The two distinct cycles of length 4 (namely c1 = {1, 2} + {2,3} + {3, 4} + {4, 1} and c2 = {5, 6} + {6, 7} + {7, 8} + {8, 5})
present in the network generate two one-dimensional
homology classes that appear at index 1 (Rips complex
K1) but are not present in K0. There is also one cycle of
length 3: c3 = {1, 5} + {5, 9} + {9, 1}. Each of these three cy-
cles gives birth to one dimension in Z1
1. However, only the
two cycles of length 4 c1 and c2 remain as homology
classes in H1
1 because c3 is the boundary of the two-
dimensional simplex {1, 5, 9} that belongs to K1. (because
all its faces are elements of K1. . Hence c3 belongs to B1
1
and kills the homology class created by {1, 5, 9} in Z1
1. At
index one we thus have β1
1,1 = 2, explaining the two bars in
Fig. 1c. They disappear at index two because c1 and c2 be-
come boundaries. In K2, four edges are added to the ones
already present in K1, namely {1, 3}, {2, 4}, {5, 7} and {6, 8}
because they are between vertices {v}, {w} that are such
that d(v,w) ≤ 2. These new edges (the yellow edges in
Fig. 1) give birth to new two-dimensional simplices such
as {1,2,3} and {1,3,4}. These fill the holes created by cycles
c1 and c2 and consequently kill the two associated hom-
ology classes. It explains why β1
1,j = 0, for all j ≥ 2 and why
the two bars in Fig. 1c last from index 1 to 2. This example
shows that essential β1
1,1 records the number of independent
cycles of length 4 or more in the network. Cycles of length
4, 5 or 6 are killed when distance between two edges
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to two. Larger cycles give longer-lasting one-dimensional
homology. For instance a cycle of length 7 would give a
homology class lasting from index 1 to 3. These simple ex-
amples of networks with one-dimensional cycles do not
exhibit homology (holes) of dimension higher than one.
Such features are obtained with slightly more complex
graphs such as the one that would be obtained from the
graph of an octahedron and its edges (one two- dimen-
sional homology class created at index 1 and lasting until
index 2).
In summary, the homology measures we defined, per-
sistent homology/ Betti numbers are measures of (i) the
number of independent n-dimensional cycles, and (ii)
the amount of connectivity that would be needed in
order to annihilate these cycles. These homology mea-
sures are therefore sensitive metrics of the network com-
plexity and, depending on the node location and its
connectivity, its removal from the network may have sig-
nificant or insignificant effect.
Results and discussion
We computed the Betti number for each cancer network
and plotted that value versus the five-year survival rate.
This is shown in Fig. 2. The R correlation is −0.55 and
the p-value is 0.079. We systematically removed each
node in each network and recorded the change in Betti
number. The single node protein removal that resulted
in the largest drop in Betti number also resulted in theFig. 2 Mapping of Betti numbers onto survival data from Surveillance Epid
were calculated on the Kyoto Encyclopedia of Genes and Genomes (KEGG)
Database (SEER). Nominal Betti, a measure of network complexity, was inve
suggesting an inverse relationship between network complexity and cancelargest drop in complexity, and as we discuss below, is
potentially a good drug target. These results are shown
in Table 1. We also systematically removed two proteins
from the network and recomputed the Betti number to
observe which double inhibition would lead to the low-
est Betti number. These results are shown in Table 2.
Overview of results
Betti numbers and cycle-basis are used to describe a
measure of complexity of the PPI networks within the
cancer pathway networks. The Betti number is a meas-
ure of the number of the cycles with four or more nodes,
whereas cycle-basis is the number of cycles with three or
more nodes. Our analysis of persistent homology of can-
cer networks revealed that a particular Betti number,
symbolized as β1
1,1, was highly correlated with survival.
This particular Betti number represents the number of
one-dimensional homology classes of the network. We
focus only on this number in the subsequent text, and
simply refer to it as the Betti number associated with the
network. This Betti number is linearly correlated (R =
0.932) with cycle-basis. In general, a Betti number repre-
sents a topological measure – an abstraction – of the net-
work. The abstraction of the network into Betti numbers
facilitates an analysis of the correlation between Betti
numbers and percent survival. The mapping the Betti
numbers space onto the survival curves using a compu-
tational algorithm, indirectly maps the PPI-space onto
survival space. This indirect mapping is of centralemiology and End Results (SEER) database. Nominal Betti numbers
and correlated with Surveillance, Epidemiology and End Results
rsely correlated with percent 5-year survival (R = −0.551, p = 0.0789),
r survival
Table 1 Betti number analysis and its implication for single protein targeting. The Surveillance, Epidemiology and End Results
Database (SEER) provide data for the 5-year survival, degree-entropy was calculated from the Protein-protein interaction network (PPI)
using Python®, Cycle-Basis was calculated using networkX.cycle_basis (a Python function), the nominal Betti number was calculated using
JPLEX, and represents the Betti number for the full cancer network, and the Best Betti represents the lowest Betti number achieved by
removal of a protein from the specific cancer PPI network. Degree-entropy and cycle basis are provided only as alternative measures of
network complexity. When the elimination of proteins generated the same reduction in Betti, they were considered “equivalent
targets”. A node connecting two clusters of proteins would be considered a node with high betweeness. We used highest
betweeneness-centrality to differentiate equivalency targets, and the shaded entries have lowest Betti numbers and high
betweeness centrality in the specific cancer
AML Bladder CML Colorectal Endometrial Glioma NSCL Pancreatic Renal SCL Thyroid
5 years Survival [%] 23.6 78.1 55.2 63.6 68.6 33.4 18 5.5 69.5 6.2 97.2
Degree-Entropy 2.16 1.52 2.11 1.63 1.6 2.22 2.23 2 1.59 2.06 1.38
Cycle-Basis 108 20 115 58 45 128 75 72 52 150 24
Nominal Betti 107 20 114 51 45 128 50 38 51 149 24
Best Betti 95 15 101 41 35 109 37 29 34 131 17
Equivalent Targets FLT3 ITGA3
HRAS MAPK3 AKT1 AKT3 HRAS ITGA6 HRAS
NRAS MAPK1 AKT2 AKT2 PDPK1 NRAS KRAS KRAS HIF1A ITGA2B NRAS
KRAS AKT3 AKT1 ILK KRAS EPAS1 ITGB1 KRAS
ITGA2
ITGAV
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network information into a single number, and this
abstraction is associated with a particular amount of
uncertainty. Thus, the uncertainty of mapping Betti
number-space to percent survival-space leads to a sig-
nificant increase in uncertainty. Because many networks
can give rise to the same Betti number (surjective map-
ping), Betti number mapping to survival must be done
with this caveat in mind.
The actual mapping of Betti numbers onto the Surveil-
lance Epidemiology and End Results (SEER) database
(Fig. 2) revealed an inverse linear correlation (R = −0.551,
p-value 0.079) between Betti number (a dimension of per-
sistent homology from filtration index one to two) and
percent 5-year survival for a variety of cancers. The in-
verse correlation implies that the higher the Betti number,
the lower the probability of five-year survival. Our interest
in this approach lies not simply in describing this map-
ping, but rather in using such a mapping for developing
tools for evaluation of therapeutic targets and designing
personalized therapies.
A similar correlation was reported previously for the
relationship between the degree-entropy and survival
mapping [1], where the authors concluded that a tar-
geted removal of a single protein from the network (the
clinical equivalent of this would be a pharmacological in-
hibition of the protein) resulted in very little change in
the degree-entropy unless the protein was a key hub (a
protein with large number of connections to otherproteins). Given the negative correlation of survival and
Betti numbers in our framework, the elimination of a
protein from the network leads to a decrease in Betti
number. The degree of Betti number change corre-
sponded to the importance of the protein in the net-
work. Consequently, when the elimination of a protein
from the network leads to a much lower Betti number,
the protein represents a potential therapeutic target. In
contrast, the elimination of proteins in the periphery of
the network (i.e. leaf nodes that have only one connec-
tion) has little or no impact on Betti number, degree-
entropy, or cycle-basis. In contrast, the targeted elimin-
ation of hub proteins (those with a large number of con-
nections) can lead to collapse of the network, and such a
target may not be the best to be explored therapeutically.
Potential therapeutic targets with high impact on the
network can be investigated as sets of proteins. Even
though the elimination of proteins internal to the net-
work can lead to small changes in degree-entropy [1], it
had a significant impact on the Betti number, suggesting
that the use of Betti numbers in evaluation of network
complexity is superior to degree-entropy.
Discussion of Table 1
The ability to use persistent homology and complexity
of cancer PPI networks for the exploration of the im-
portance of specific cancer-related proteins has a great
potential for distinguishing “driver” mutations from those
that represent “passenger” events. Because Betti numbers
Table 2 Betti number analysis and its implication for multiple protein targeting. The data for the 5-year survival was again derived from Surveillance, Epidemiology and End Results
Database (SEER), the nominal Betti number was calculated using JPLEX, and represents the Betti number for the full cancer network, and the Best Betti represents the lowest Betti
number achieved by removal of a protein from the specific cancer protein-protein interaction (PPI) network. Through sequential removal of protein pairs across the entire PPI network
of each cancer, we were able to identify combinations of protein pairs exhibiting most effect on the PPI network. Shown are the node combinations which produce the most reduc-
tion in network complexity as measured by the “Best Betti, double node elimination”, each paired node elimination results in equivalent drop in Betti, e.g. HRAS-FLT3 and HRAS-NRAS
both have Best Betti of 83 in AML
AML Bladder CML Colorectal Endometrial Glioma NSCL Pancreatic Renal SCL Thyroid
5 years Survival [%] 23.6 78.1 55.2 63.6 68.6 33.4 18 5.5 69.5 6.2 97.2
Nominal Betti 107 20 114 51 45 128 50 38 51 149 24
Best Betti [single
node elimination]
95 15 101 41 35 109 37 29 34 131 17
Best Betti [double
node elimination]
83 11 88 31 26 90 29 21 26 113 10
Paired node elimination HRAS – MAPK3 ITGA2 – ITGA3
ARAF – MAPK3 ITGA2 – ITGA6
RAF1 – MAPK3 ITGA3 – ITGA6
HRAS – FLT3 NRAS – MAPK3 ITGA2 – ITGA2B
HRAS – NRAS HRAS – MAPK1 AKT1 – AKT2 AKT1 – AKT2 NRAS – HRAS ITGA3 – ITGA2B HRAS – NRAS
FLT3 – NRAS ARAK – MAPK1 AKT1 – AKT3 AKT1 – AKT3 ILK – PDPK1 NRAS – KRAS EGFR – KRAS NFKB1 – KRAS HIF1A – GAB1 ITGA6 – ITGA2B HRAS – KRAS
HRAS – KRAS RAF1 – MAPK1 AKT2 – AKT3 AKT2 – AKT3 HRAS – KRAS ERBB2 – KRAS RELA – KRAS GAB1 – EPAS1 ITGA2 – ITGB1 NRAS – KRAS
FLT3 – KRAS NRAS – MAPK1 ITGA3 – ITGB1
NRAS – KRAS MAPK3 – KRAS ITGA6 – ITGB1
MAPK1 – KRAS ITGA2B – ITGB1
MAPK3 – BRAF ITGA2 – ITGAV
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ination of multiple protein inhibitions, they can be used
for defining combinatorial therapies. An analysis of the ef-
fect(s) of inhibiting a single node (Table 1) or multiple
nodes (Table 2), the respective Betti numbers and percent
5-year survival, provides implications for drug targeting.
The “nominal Betti number” is the Betti number calcu-
lated from the intact KEGG/PPI cancer network. The
“best Betti number” is the lowest Betti number obtained
by removal of a protein from the specific cancer PPI net-
work. We include in Table 1 degree-entropy and cycle
basis as alternative measures of network complexity for
comparison. While in present clinical practice it is ac-
cepted to treat any change in protein expression (com-
pared to normal tissues) as equivalent in importance, the
findings in Table 1 suggest otherwise. Some of the pro-
teins have a significant effect on the integrity of the
network while others come along for the ride. For
example, the ras family of proteins is very important in gli-
oma, and removing one of HRAS, KRAS or NRAS leads
to a significant decrease in network complexity, reflected
in 15 % reduction in Betti number, a decrease from 128 to
109 (Table 1). In comparison, the role of the ras family of
proteins is less important in chronic myeloid leukemia or
endometrial cancers. In these cancers, removing any single
ras family member had little impact on the complexity of
the respective cancer networks, yielding only 4 % and 9 %
Betti number reductions (from 114 to 110 and from 45 to
41 respectively, data not shown). Similarly, in non-small
cell lung cancer (NSCLC), and in pancreatic cancer, KRAS
appears to be one of the main drivers, and its targeting
leads to a drop in Betti number from 50 to 37 (26 % re-
duction) for NSCL, and a drop from 38 to 29 (24 % reduc-
tion) for pancreatic cancer (Table 1).
Discussion of Table 2
Betti numbers may therefore provide invaluable informa-
tion in choosing combinatorial therapies. For example,
targeting KRAS and EGFR together (or equivalently
KRAS and ErbB2) leads, in the case of NSCL, to a syner-
gistic reduction in complexity, and Betti number drops
further from 37 to 29 (Table 2). Similarly, in acute mye-
loblastic leukemia (AML), a very hard to treat cancer
with survival between 20 and 30 % for some of its sub-
types, FLT3, HRAS, NRAS and KRAS mutations appear
to have an equivalent effect in their ability to suppress
the complexity of the cancer network (Betti number
drops from 107 to 95). Moreover, data summarized in
Table 2 suggests that a combination of two targets may
lead to further enhancement of the effect. The elimin-
ation of both RAS and FLT3 for example, leads to a drop
in Betti number to 83.
Cancer networks represent a very complex and highly
interactive space. Reducing this complex information toa representative Betti number may facilitate clinically
meaningful predictions of treatment response. In [1] we
published a method of measuring complexity based on
high betweenness-centrality. The term describes the fre-
quency of short connections between two nodes, and
implies that breaking these connections can lead to
destruction of the network connectivity. However, the
decrease of betweenness-centrality in this earlier publica-
tion did not always translate into a decrease in complexity
as measured by degree-entropy. Combining information
about high betweenness-centrality and Betti number (see
shaded areas in Table 1) led to meaningful improvement
in the accuracy of predicting clinical response. For ex-
ample, in endometrial cancer, a PDPKI protein has both
the highest betweenness-centrality (shaded in Table 1) and
the highest drop in Betti number, suggesting it may be a
very strong candidate for drug development.
Detailed examples
Thus, to understand how Betti number could translate
to development of biologically- based therapies, we start
with the elimination (inhibition) of a specific protein
within a particular network. The protein-protein inter-
action (PPI) network for AML based on KEGGgraph
(Fig. 3a) graphically depicts the best targets determined
by Betti number. FLT3, which has high betweenness-
centrality can be seen to connect two sub-neworks. The
beneficial effects of inhibiting NRAS and FLT3 simultan-
eously is evident in Fig. 3b. The network breaks into two
“components” but the inhibition does not result in a
complete destruction of the network, which would have
been potentially lethal. The details of the ras family of
proteins effect are depicted in Fig. 4. NRAS, KRAS, and
HRAS, appear to be completely equivalent in their
linkages, suggesting biological redundancy (see Fig. 4b
where NRAS and its linkages have been removed). The
topology shows that any of the RAS family proteins are
very good targets in AML, bladder, glioma and thyroid
(Table 2). However, in NSCL and pancreatic cancer
only KRAS plays a significant role (Table 1). This is
consistent with the present understanding in the clin-
ical community [16].
Note that the elimination of FLT3 and any one of the
RAS proteins leads to break down of the network into
two separate components as well as thinning of the
major network, suggesting that the combination of
agents that inhibit both subnetworks would be synergistic.
This double protein inhibition resulted in greater reduction
in Betti number from 107 to 83 (Table 2). This reduction
is again strongly correlated with survival. While complete
destruction of the network appears to be possible by tar-
geting all three RAS proteins along with the FLT3, such
an approach is suggestive of significant toxicities as it
collapses all physiological pathways.
Fig. 3 Analysis of the Protein-Protein Interaction network for Acute Myeloid Leukemia. Protein-protein interaction network (PPI) for AML was obtained
from Kyoto Encyclopedia of Genes and Genomes (KEGG) and converted into the figure present in Panel a using R-script known as KEGGraph. It reveals
a complex single component network, which breaks into two separate components by targeted elimination of the connecting FLT3 protein. The effect
of simultaneous elimination of NRAS and FLT3 (Panel b) leads not only to break down of the network into two separate components, but also
to thinning of the main network
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In summary, our work suggests that Betti numbers may
represent a sensitive measure of network complexity and
may be useful for optimizing the design of protein-
protein interactions within networks. Because the reduc-
tion of network complexity achieved by elimination of
one or more proteins from the PPI network can be cor-
related with changes in survival rates, the method holds
potential for optimization of targets for personalized tar-
geted therapies. The most reassuring finding, a post-
diction, was that the mathematical derivation of Betti
number calculations, “discovered” a number of drug tar-
gets successfully used for treatment in clinics and per-
forming well in clinical trials. Similarly, clinical trialsusing targets whose elimination did not lead to a signifi-
cant drop of Betti number were not successful. It is
likely that the use of mathematics in medicine would de-
crease the frequency of negative clinical trials as well as
provide timely information about the best drug combin-
ation for individual patients.
Methods
For most cancers a great deal of molecular information is
now available. The information has been for many cases
compiled, curated, and posted at the Kyoto Encyclopedia
of Genes and Genomes (KEGG) [17], and is publicly avail-
able at http://www.genome.jp/kegg/pathway.html. Simi-
larly, detailed statistical information about the five-year
Fig. 4 Effect of elimination of more than one Betti-derived targets from the Acute Myeloid Leukemia Protein-Protein Interaction network. The AML PPI
network was imported into Cytoscape®, and all nodes except for the RAS family and their neighbors, were eliminated for graphical purposes only. As
seen in panel a, the RAS family of proteins indicates that each of respective proteins (HRAS, KRAS and NRAS) is equivalent in importance and
interconnected with similar neighbors. Panel b shows the effect of inhibition of NRAS and the resulting reduction in complexity
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the Surveillance Epidemiology and End Results (SEER)
National Cancer Institute database. We have previously
published the details of how the KEGG pathway data
can be converted into protein-protein interaction net-
works [1]. Briefly, the approach involves processing the
KGML files representing the pathway network using a
software program known as KEGGgraph [18] available
at Bioconductor (http://www.bioconductor.org/packages/
2.4/bioc/html/KEGGgraph.html). The R-script converts
the KEGG file into an adjacency list for a protein-protein
interaction (PPI) network, and using DAVID [19] (http://
david.abcc.ncifcrf.gov/) one can convert the Entrez IDs
into gene symbols. Cytoscape [20] can then be used for
visualization and analysis of the PPI networks. The
betweenness-centrality was calculated using the Py-
thon code networkx.betweenness_centrality(G), and
the betweenness-centrality values were confirmed with
a Cytoscape Network Analysis plugin.
To compute the persistent homology/ Betti numbers
associated with the cancer networks, we used the Matlab
implementation of a software package for JPlex (http://
www.swmath.org/software/9851).
Reviewers’ comment
Reviewer 1: Dr. Nathan J. Bowen (nominated by Dr. I.
King Jordan): Clark Atlanta University, United States of
America
While the formal mathematical work is sound, the lack
of measurements of the actual protein levels (nodes)
precludes any biological insight that can be gained by
measuring the topology of the network. Just because a
protein is listed in the signaling network, it doesn’t mean
that it is present in the diseased state. Many proteins
(nodes) that may represent potential tumor suppressors
in each of the pathways presented are often lost incancer or their expression level is severely reduced. Can-
cer KEGG pathways draw from what is known about the
circuitry of signaling pathways that have been deduced
from the study of multicellular embryonic development
as well as cancer.
In the case of embryonic development, the pathways
are meant to include the necessary components for “wild
type” development, that is, functional pathways that lead
to “healthy” cellular homeostasis. Cancer is considered a
genetic disease. Mutations that lead to loss of proteins
(tumor suppressor nodes) or gain or overexpression of
proteins (oncogenic nodes) are detected in virtually all
cancers analyzed. Therefore, some measure of expres-
sion level, or present/ absent value must be assigned to
each node in a healthy state vs. a cancer state before dif-
ferential topological calculations can produce meaning-
ful biological insights that translate into clinical decision
making at the treatment and progression levels.
In a publication by West J, Bianconi G, Severini S,
Teschendorff AE. Differential network entropy reveals
cancer system hallmarks. Scientific Reports 2012;2:802.
doi:10.1038/srep00802 the authors actually find that “the
average of the absolute correlations over neighbours of
a given node provides an equally good discriminator
(Fig. S4), indicating that the loss of local connectivity is
a key cancer characteristic.”
We also see a similar loss of connectivity in networks
that we construct using gene expression data, that is, a
reduction in the number of correlated gene pairs in can-
cer cell gene expression networks when compared to
healthy cell gene expression networks.
The measure of persistent homolog is a highly plaus-
ible description of signaling network topology in bio-
logical systems. It is also a highly attractive measure to
use when calculating differences between networks when
nodes are removed as the authors have described here.
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quantification, persistent homology will surely be incor-
porated in experimental manipulation of node knock-
out in living cells as is now routinely accomplished using
CRISPR/Cas9 gene editing technology.
However, until quantities or at least presence/absence
values are given to nodes in healthy vs. cancer states, I
don’t feel that it is a reliable measure that can be used in
the biological, much less clinical, interpretation of sig-
naling or protein-protein interaction networks.
Author response to reviewer number 1
We agree with the reviewer that just because a protein is
present in the KEGG signaling network for a specific
cancer, does not mean it is differentially expressed be-
tween cancer and healthy tissues. We need to stress here
that no information about gene expression is explicitly
embedded in the KEGG networks, and as such it is not
considered in our calculation of Betti numbers. The Betti
number, as a measure of complexity of a protein-protein
interaction network, simply reflects the number of cycles
of four or more connected nodes. There is also no em-
bryonic pathway information embedded in the cancer
KEGG pathway networks. The KEGG pathways, not just
cancer pathways, are constructed and curated by re-
search staff at the Kyoto University, who read literature
and manually build-in the connections. For example, a
cancer such as glioblastoma will have its pathway built
as an average pathway for that cancer. It does not and
cannot include mutation information, or specific patient
or cancer stage information. We used the KEGG net-
works in order to exploit protein-protein interactions for
each cancer, and to analyze the topology of those net-
works. While our long-term goal is finding a technique
to assist clinicians in their decision making, this manu-
script presents a method of measuring PPI network com-
plexity and provides some simple examples of how this
method can, independently of expression data, point to
those genes that are of importance. There is ongoing
work to merge this topology measures with expression
data and refine cancer specific approaches.
This also explains why the research report of West,
et al. is not relevant. The report combines a fixed PPI
network architecture with mRNA expression data to de-
rive uniquely weighted networks for each of cancers they
studied. Their weighted networks have fixed architecture
across all cancers. Our architecture of the PPI network
is NOT fixed. Our analysis is strictly based on topology
of these unique networks, making Dr. West’s method
singularly different from ours. One may view the two
methods as potentially complementary methods for drug
target selection. Dr. West’s team found that local en-
tropy is a key factor in determining potential targets,
and they were able to deduce important informationabout robustness of a particular node within the network.
Their target suggestions are based mainly on mRNA ex-
pression levels across a population of samples. A protein
with a very highly up-regulated mRNA expression is as-
sumed to be of importance in the network – they do not
actually compute network entropy. This is how many tar-
gets are presently “discovered”, by assuming that the
strength of up- or down-regulation of a gene reflects its
importance.
Our method, in contrast, analyzes each of the cancer
PPI network as a unique network and avoids biasing its
complexity with expression data. The shortfall of course
is that the method relies on the quality of the KEGG PPI
networks. However, it is extremely reassuring that des-
pite the uncertainty associated with KEGG networks in-
formation, there is a strong correlation between network
complexity and survival data from SEER.
Reviewer 2: Dr. Tomasz Lipniacki Rice University, United
States of America
Comments on Design Principles for Cancer Therapy
guided by changes in complexity of Protein-Protein
Interaction Networks by Benzekry et al. The Authors
introduce topological measures of protein-protein inter-
action networks, such as Betti numbers (related to the
structure of cycles in the interaction graph). Next, they
analyze 11 cancer interaction networks to found that
Betti number #11,1 (which measures the number of in-
dependent cycles of length larger than 3) correlates
(negatively) with 5-year survival rate (Fig. 2). After that,
they look into nodes, which removal lead to the highest
decrease of Betti numbers, and also found pairs of such
nodes. They propose that such nodes are good candi-
dates for cancer therapy, as removing such nodes would
substantially reduce complexity of network topology.
The presented results are interesting and in a sense in-
tuitive. Larger Betti numbers correlate with networks
connectivity and therefore its robustness to perturbation,
which may imply stronger persistent of cancer network
to therapy.
I think however, that the conclusion in which authors
state that nodes which removal lead to the greatest re-
duction of network complexity goes a bit too far. First,
cancer networks consist of proteins that have prosurvival
(from cell perspective) and proapoptotic roles. Removing
highly connected nodes with proapoptotic “action”
would even worsen the prognosis. Second, nodes im-
portant for cancer network complexity, are likely to be
important in non-cancerous cells, and therefore therapy
which aims in blocking these nodes may have lethal
sides effects. The Authors should discuss these points.
I think also that the statistics of 11 considered net-
works is too small to conclude (prove) that Betti number
#11,1 is the best topological measure (i.e. with the
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removing just two points (say with the highest 5-years sur-
vival) would reduce correlation close to zero. One can thus
think that having only 11 networks in analysis, it is possible
to choose such a topological measure of the networks
that would negatively (or positively) correlate with survival
prognosis, even if there is no real correlation.
The credibility of study would be increased by analysis
of the substantially larger number of cancer networks, or
maybe other (non-cancer) networks for which the simi-
lar reasoning is possible, to show that Betti number
#11,1 is a good measure of network robustness.
Authors response to reviewer number 2
We agree with the reviewer that the conclusions we
draw about utility of Betti numbers as a measure of
complexity may not be on its own sufficient for target
selection. We simply imply that analysis of network
complexity may initiate development of mathematical
tools that may lead to a more rational selection of tar-
gets. We also agree with the reviewer that many other
network measures should be and were explored in evalu-
ating the degree of correlation between complexity of
cancer PPI networks and five-year survival. For example,
in addition to Betti numbers, we examined the following:
degree entropy, number of leaf nodes, leafs per node,
leafs per edge, leafs per component, average and stand-
ard deviation of degree, closeness centrality, clique, tran-
sitivity, assortivity, node count, edge count, number of
connected components, the first five eigenvalues of the
adjacency matrix, and the first five eigenvalues of the
Lapalcian matrix. We only found three useful measures:
Betti number, number of leafs, and degree entropy. We
published a manuscript describing the correlation be-
tween degree entropy and survival (PMID: 22615392,
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9209-12).
However, we found that computing the degree entropy
after removing a node from the network led to a very
small change in entropy, and the interpolation of this
value on an entropy/survival curve was insignificant. We
have not as of yet looked at whether the number of leafs
as a metric may be useful. It was our goal to find a net-
work metric, which would show a linear correlation with
survival. In Betti number we found a metric with suffi-
ciently robust change following removal of a node, that
its interpolation on the linear Betti/survival curve could
be predictive of a meaningful change in survival.
We also agree with the reviewer that many of the
nodes important for cancer network complexity, are
likely to be important in non-cancerous cells. This is a
concern for most medical therapies and cannot be
underestimated. However, there are many steps between
the identification of a potential target and development
of an agent, and for pathways that are vital to life weoften chose a downstream inhibition, one that manages
the symptoms rather than directly inhibits a node. A
good example is the KRAS pathway, it is vital to life, but
patients with systemic disorder such as RAS-associated
lymphoproliferative disorder (RALD) can be maintained
on thalidomide/sirolimus, which act downstream/paral-
lel to this pathway. Thus, if a therapy, which aims in
blocking a vitally important node(s), is likely to be asso-
ciated with lethal sides effects, a downstream inhibition
of the pathway should be the approach.
Finally, the reviewer recommends increasing the num-
ber of cancer networks analyzed for our study. Unfortu-
nately, there is a scarcity of well-curated, trustworthy
data that can be used for this purpose and we analyze all
of the networks available in KEGG. While there may be
other institutional or laboratory based data sets, they are
not available to us. We have used all the KEGG net-
works for which good statistical data could be obtained.
Reviewer 3: Dr. Marek Kimmel Rice University, United
States of America
Application of gene and protein networks is likely to
help tackle various issues in molecular evolution of can-
cers and from this viewpoint this is an interesting paper.
My criticism of the paper has more to do with the way
the authors interpret data.
1. Tumor stratification by stage at diagnosis and cell
type. Survival in most tumors is correlated inversely
with stage at diagnosis. If deregulation of gene or
protein network also depends on stage (quite likely),
this will create association even if causality is absent.
Therefore, stratification by stage is so important in
cancer studies. SEER database includes stage
information for major cancers such as for example
lung cancer. In my opinion, the data analysis section
should be supplemented by stratified analyses.
2. It is known that given sufficiently many parameters
(or for example, many possible arrangements of
mutations over the nodes of a network) it is possible
to find some that correlate with outcome such as
survival. Therefore, it is useful to randomly split the
data set into test and validation samples. If the test
developed works satisfactorily in the validation
sample, then this makes it plausible. SEER or
another database will be helpful for this purpose.
3. Relationship in Fig. 2 looks much more parabolic
than linear, and the interpretation of Betti index
value will be quite different in this latter case.
Author’s response to reviewer number 3
1. We agree with the reviewer, that analysis by stage at
diagnosis and cell type would have been of interest.
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data, KEGG does not. The KEGG PPI networks are
an average of many known networks for each
specific cancer. We discuss the characteristics and
construction of KEGG networks in our response to
Reviewer 1. While, as the reviewer points out
survival in most tumors is correlated inversely with
stage at diagnosis, and while it is likely that deregulation
of gene or protein network also depends on stage, the
intention was not to create associations, but rather
create an understanding about PPI networks and how
to measure changes occurring with removal of a node.
While stratification by stage is very important in
cancers, stratified analyses may be difficult using
present databases.
2. We understand the concept of leave-one/-many-out
for cross validation. This is commonly done with
machine learning algorithms. However, this was not
a machine learning algorithm or algorithm using any
kind of mapping. The method used here was
straightforward evaluation of the relationship
between a complexity measure of a PPI network and
survival. Furthermore, KEGG does not provide any
mutation information and the effect of mutation on
networks could not be evaluated with KEGG. The
individual cancer networks, as provided, are fixed
averages across the number of subjects interrogated
for the data.
3. We agree with the reviewer that a parabola could
have been fitted to the sample set of cancers
available in KEGG. It is likely, however, that this
observational artifact is due to the paucity of
information of more cancer types. As more data
emerges, perhaps the study could be redone, and
confirmed. Furthermore, fitting a parabola would be
less helpful as we would have two sets of survival
numbers for each Betti number. We do not
advocate indiscriminately accepting the Betti
computations, we provide a recommendation
of an approach that can be further studied and/or
combined with other methods of network
interrogation.
Author’s response to second review by reviewer 1: Dr.
Nathan J.Bowen (nominated by Dr. I.King Jordan), Clark
Atlanta University
I would just like to point out that all KEGG pathway
edges are not meant to represent protein-protein in-
teractions. Many, for transcription factors, actually
represent protein-DNA interactions. That is, the tf
binds to the DNA in the promoter of the next node in
the pathway. Also, the KEGG pathways do include
mutation data. Both of these facts can be seen in the
pathway for AML that the authors use, perhapsincorrectly, in their manuscript. The retinoic acid re-
ceptor, alpha (RARA) in Fig. 3 is one such transcrip-
tion factor that regulates CCNA1 and JUP. The RARA
in Fig. 3 is connected with an edge directly to CCNA
and JUP even in the absence of direct protein-protein
interaction. Likewise, the RARA in AML is depicted as
two fusion genes in the KEGG pathways, PML-RARA
and PLZF-RARA. The authors fail to include this in
their pathways as well. This makes one question
whether the authors took into account the regulatory
interactions, that is, protein-DNA interactions that are
depicted as edges in the KEGG pathways and main-
tained the fusion or other mutation data included
from KEGG. In addition, the NFKB node that is re-
moved in Pancreatic Cancer is a transcription factor
and thus would only connect to DNA from one side in
said network. For these reasons, I believe the authors
should publish the tab delimited text files of the interaction
networks used, so one can see how many transcription
factor to target genes were included as protein-protein
interactions. Likewise, the authors may wish to examine
their title in which they explicitly reference protein-
protein interactions.
Author’s response to the second review by Reviewer 1
Dr. Nathan J.Bowen
The KEGG networks are available from the KEGG web-
site (www.KEGG.jp) and we now include images of the
website as Additional file 1: Figure S1. As the reviewer
points out, even though the KEGG maps consist not
only of proteins but also of RNA, DNA and small mole-
cules, and even though some of the interactions may
represent protein-DNA interactions we do not focus on
these. We have, for the purposes of this manuscript, fo-
cused on the protein-protein interaction network as
generated by R-script KEGGgraph (described in the
methods section). We also do not elaborate on mutation
data, because mutation data are not embedded in the
KEGG network, but rather link to these networks. The
reviewer’s example of the PML-RARA interaction is not
part of the main KEGG interaction map because these
are abstracted away by KEGGgraph. The real human
biology is immensely complex and we are in the early
stages of accumulating the content of gene-gene, protein-
protein or protein-gene interaction networks. While we
share the reviewer’s concern about the incompleteness of
these data sets, the mutation and fusion information is
not produced in KEGGgraph operation for analysis. As re-
quested, we now include the adjacency lists of the protein-
protein interaction networks in Additional file 2: Table S1.
We carefully considered the suggestion to reference other
interactions in the title, but had concerns it may be mis-
leading since our calculations are limited to protein-
protein interactions.
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Additional file 1: Figure S1. Diagrams of the Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways for 11 cancers. The symbols used
in the diagrams are summarized on the first page, and each specific
cancer type is on subsequent pages in order of acute myeloid leukemia,
bladder carcinoma, chronic myeloid leukemia, colorectal cancer,
endometrial carcinoma, glioma, nonsmall-cell lung carcinoma, pancreatic
carcinoma, renal cell carcinoma, small cell lung cancer, and thyroid can-
cer. All diagrams were downloaded from the KEGG PATHWAY Database
(http://www.genome.jp/kegg/pathway.html).
Additional file 2: Table S1. Adjacency Lists of proteins comprising the
protein-protein interaction networks. It provides the EntrezID® for each
protein and the respective gene symbols.
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